<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>


Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology for the detection and monitoring of circulating tumor DNA (ctDNA) in urine and blood. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally. 

November 9, 2016
2:00pm - 3:30pm PST

Trovagene will report financial results for the third quarter ended September 30, 2016 on Wednesday, November 9, 2016 at 4:00 p.m. Eastern Standard Time (1:00 p.m. Pacific Standard Time).

Trovagene’s senior management team will host a conference call on Wednesday, November 9, 2016 at 5:00 p.m. Eastern Standard Time (2:00 p.m. Pacific Standard Time) to discuss the results and update investors on the Company’s progress.

October 19, 2016
2:00pm - 2:25pm PDT

Trovagene's Chief Executive Officer, Bill Welch, will be presenting Wednesday, October 19th at 2:00pm PDT at the BIO Investor Forum in San Francisco at the Westin St. Francis Hotel. The...

September 12, 2016 - September 13, 2016

Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D. will be presenting; Clinical Utility for Detection and Monitoring Circulating Tumor DNA from Urine and Plasma, at the 3rd Precision...

email print
Stock Information
Contact Investor Relations

Direct     [USA +1] 858-952-7593

E-mail    ir@trovagene.com